A recent article published in Pathology showed that 18/18 intestinal resection samples from Crohn’s disease patients contained mycobacteria. In contrast, none of the 15 samples from control subjects were positive.

Human Paratuberculosis Foundation is dedicated to providing the latest research and information about the role of Mycobacterium avium subsp. paratuberculosis (MAP) in chronic immune conditions such as Crohn’s disease, multiple sclerosis, Type 1 diabetes, ulcerative colitis, sarcoidosis, Parkinson’s disease, rheumatoid arthritis, lupus and more. Our goal is to assist researchers, health care professionals and patients around the world. We are grateful for the support of our community and look forward to taking this journey together. Enjoy the latest edition of our quarterly newsletter!

This week the world lost a friend, colleague and advocate for IBD patients. For decades, Patrick McLean dedicated his talents to advancing research into anti-mycobacterial treatment solutions for chronic immune diseases such as Crohn’s and multiple sclerosis. He had great compassion for patients, and exemplified the best of humanity. Our community was blessed to have known him, and he leaves a legacy that will ripple throughout time.

Human Para’s second research, which sought to detect MAP in blinded blood samples from Crohn’s and control pediatric subjects, has now concluded. Read on to see the results.

Human Paratuberculosis Foundation is dedicated to providing the latest research and information about the role of Mycobacterium avium subsp. paratuberculosis (MAP) in chronic immune conditions such as Crohn’s disease, multiple sclerosis, Type 1 diabetes, ulcerative colitis, sarcoidosis, Parkinson’s disease, rheumatoid arthritis, lupus and more. Our goal is to assist researchers, health care professionals and patients around the world. We are grateful for the support of our community and look forward to taking this journey together. Enjoy the latest edition of our quarterly newsletter!